Skip to content

Study · Randomized controlled trial · n = 13 · 2018

4 results

Teriparatide for treatment of patients with bisphosphonate-associated atypical fracture of the femur.

Greenspan SL, Vujevich K, Britton C, Herradura A, Gruen G, Tarkin I, Siska P, Hamlin B, Perera S

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA30 Oct 2017Cited by 37 (Europe PMC)

PMID29085957 (opens in a new tab)PMCIDPMC6468986 (opens in a new tab)DOI10.1007/s00198-017-4286-7 (opens in a new tab)PepBankPUB-29085957
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with atypical femur fractures, immediate teriparatide showed a trend toward better composite healing than delayed therapy at 6 months.

    In plain wordsIn women with atypical femur fractures, immediate teriparatide showed a trend toward better healing than delayed treatment at 6 months.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseComposite fracture healing at 6 months
    Study

    n = 13

    Comparator
    Teriparatide delayed by 6 months
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Composite healing score
    12.6 points
    immediate at 6 months
    Composite healing score
    11.2 points
    delayed at 6 months

    Source sentences

    Summary
    We found there was a trend for superior healing with the composite score (12.6 vs 11.2 at 6 months and 15.4 vs 13.2 at 12 months)
    2 context sentences
    Summary · context
    This randomized pilot clinical trial included 13 women with an AFF who were randomized to immediate teriparatide vs a delay of 6 months.
    Summary · context
    All were followed for 12 months on teriparatide.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with atypical femur fractures, immediate teriparatide showed a trend toward better composite healing than delayed therapy at 12 months.

    In plain wordsIn women with atypical femur fractures, immediate teriparatide showed a trend toward better healing than delayed treatment at 12 months.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseComposite fracture healing at 12 months
    Study

    n = 13

    Comparator
    Teriparatide delayed by 6 months
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Composite healing score
    15.4 points
    immediate at 12 months
    Composite healing score
    13.2 points
    delayed at 12 months

    Source sentences

    Summary
    We found there was a trend for superior healing with the composite score (12.6 vs 11.2 at 6 months and 15.4 vs 13.2 at 12 months)
    2 context sentences
    Summary · context
    This randomized pilot clinical trial included 13 women with an AFF who were randomized to immediate teriparatide vs a delay of 6 months.
    Summary · context
    All were followed for 12 months on teriparatide.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with atypical femur fractures, immediate teriparatide showed a trend toward less distal radius BMD decline than delayed therapy.

    In plain wordsIn women with atypical femur fractures, immediate teriparatide showed a trend toward less loss of distal radius bone density than delayed treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseDistal radius BMD decline
    Study

    n = 13

    Comparator
    Teriparatide delayed by 6 months
    Analysis
    Secondary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    BMD change
    −1.9%
    immediate
    BMD change
    −6.1%
    delayed

    Source sentences

    Summary
    We found there was a trend for superior healing with the composite score (12.6 vs 11.2 at 6 months and 15.4 vs 13.2 at 12 months), and lesser bone mineral density declines at the 1/3 distal radius (12-month change - 1.9 vs - 6.1%) in the immediate vs the delayed group.
    2 context sentences
    Summary · context
    This randomized pilot clinical trial included 13 women with an AFF who were randomized to immediate teriparatide vs a delay of 6 months.
    Summary · context
    All were followed for 12 months on teriparatide.
  4. 04HumanRandomized controlled trialSafety outcome

    In women with atypical femur fractures, adverse events did not differ between immediate and delayed teriparatide therapy.

    In plain wordsIn women with atypical femur fractures, adverse events did not differ between immediate and delayed teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeAdverse events
    Study

    n = 13

    Comparator
    Teriparatide delayed by 6 months
    Analysis
    Secondary
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There were no differences in adverse events.
    2 context sentences
    Summary · context
    This randomized pilot clinical trial included 13 women with an AFF who were randomized to immediate teriparatide vs a delay of 6 months.
    Summary · context
    All were followed for 12 months on teriparatide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.